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Background: Disulfiram (DS), an anti-alcoholism drug, demonstrates strong antitumor activity in a copper
(Cu)-dependent manner. This study investigates the cytotoxicity of DS/Cu complex in lymphoid malignant cell lines
in vitro and in vivo.
Method: Raji cells were subjected to different treatments and thereafter MTT assay, flow cytometry were used to
determine IC50 and apoptotic status. We also tested the cytotoxicity of DS/Cu in acute lymphoblastic leukemia cell
line Molt4 in vitro. In vivo experiments were also performed to demonstrate the anticancer efficacy of DS/Cu in Raji
cells xenografted nude mice.
Results: In combination with a low concentration (1 μM) of Cu2+, DS induced cytotoxicity in Raji cells with an IC50
of 0.085 ± 0.015 μM and in Molt4 cells with an IC50 of 0.435 ± 0.109 μM. The results of our animal experiments also
showed that the mean tumor volume in DS/Cu-treated mice was significantly smaller than that in DS or control
group, indicating that DS/Cu inhibits the proliferation of Raji cells in vivo. DS/Cu also induced apoptosis in 2
lymphoid malignant cell lines. After exposure to DS (3.3 μM)/Cu (1 μM) for 24 hours, apoptosis was detected in
81.03 ± 7.91% of Raji cells. DS/Cu induced significant apoptosis in a concentration-dependent manner with the
highest apoptotic proportion (DS/Cu: 89.867 ± 4.69%) at a concentration of 2 μM in Molt4 cells. After 24 h
exposure, DS/Cu inhibits Nrf2 expression. Flow cytometric analysis shows that DS/Cu induced ROS generation. DS/
Cu induced phosphorylation of JNK and inhibits p65 expression as well as Nrf2 expression both in vitro and in vivo.
N-acetyl-L-cysteine (NAC), an antioxidant, can partially attenuate DS/Cu complex-induced apoptosis and block JNK
activation in vitro. In addition, NAC is able to restore Nrf2 nuclear translocation and p65 expression.
Conclusion: Our study manifests that DS/Cu complex targets lymphoid malignant cells in vitro and in vivo.
Generation of ROS might be one of core steps in DS/Cu induced apoptosis. Moreover, ROS-related activation of
JNK pathway and inhibition of NF-κB and Nrf2 may also contribute to the DS/Cu induced apoptosis.
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Lymphoid malignances are tumors of the immune system.
Although treatments including chemotherapy and stem
cell transplantation are developing very fast, patients still
suffer from relapse and treatment related complications.
In order to improve the prognosis and life quality of patients
with lymphoid malignances, new therapeutic strategies are
urgently demanded.
Disulfiram (DS) is an anti-alcholism drug used in clinic
for over 60 years [1]. DS belongs to dithiocarbamate family
which is able to strongly chelate Cu and forms disulfiram/
cooper (DS/Cu) complex. DS/Cu complex is highly cyto-
toxic to many solid tumors while DS or Cu alone had few
anti-tumor effects [2-4]. However, the effect of DS/Cu on
lymphoid malignancies has not been reported yet.
Reactive oxygen species (ROS) contains a group of
oxygen-containing chemical species normally generated
from mitochondrial respiratory chain reaction with react-
ive chemical properties [2]. Cancer cells usually possess
and tolerate higher ROS activity than normal cells [3]. It
has been demonstrated that further increasing ROS expos-
ure induced by ROS-generating agents such as DS/Cu [3]
can exhaust the cellular antioxidant capacity and thus
induce apoptosis in tumor cells.
Nrf2 is a transcription factor with strong antioxidant ef-
fect which protects cancer cells from the damages induced
by ROS, anticancer drugs and other harmful chemicals
[3]. Previous publications have demonstrated the causal
relationship between Nrf2 and chemo-resistance [5-7]. So,
simultaneous down-regulation of Nrf2 and induction of
ROS in cancer cells can lead to more apoptosis.
ROS-induced apoptosis is also highly reliant on per-
sistent activation of pro-apoptotic mitogen activated
protein kinase (MAPK) pathways [8]. C-Jun NH2-terminal
kinase (JNK) is an important member of the MAPK
family [9]. Our previous study has already shown that
activation of JNK can sensitize resistant cells to antican-
cer drugs indicating the important role of JNK in drug-
induced apoptosis [10].
NF-κB is one of the major chemo-resistance-related
anti-apoptotic factors [8]. Lymphoid malignant cells pos-
sess high levels of constitutive NF-κB activity, leading to
resistance to apoptosis [7]. Thus, NF-κB is an attractive
molecular target for therapeutic intervention. Previous
studies have also shown close interactions between ROS
and NF-κB [8].
Although ROS could trigger apoptosis in cancer cells,
the ROS-induced anti-apoptotic factors, e.g. NF-κB and
Nrf2, can counteract apoptotic effects of ROS. Hence,
development of drugs that can simultaneously activate
sustained ROS pro-apoptotic pathway and inhibit NF-κB
and Nrf2 activity may improve cancer chemotherapy. This
study demonstrates that DS/Cu simultaneously activates
ROS-JNK pro-apoptotic pathway and down-regulatesNF-κB and Nrf2 anti-apoptotic pathways. Therefore, DS/Cu
shows strong anti-cancer efficacy in vitro and in vivo.
Materials and methods
Cell lines and experimental animals
Raji and Molt4 cell lines were cultured at 37°C in 5% CO2
in RPMI 1640 with 10% heat-inactivated FBS, 100 units/mL
penicillin and 100 μg/mL streptomycin. The BALB/C nude
mice (4–5 weeks of age, non-fertile, female and 18–20 g
each) were purchased from the Experimental Center of
Southern Medical University. All animal study procedures
were approved by the Southern Medical University Animal
Care and Use Committee.
Establishment of non-Hodgkin lymphoma animal model
and treatment
Mice were injected subcutaneously on the back with
1×107 Raji cells suspended in 0.2 mL sterile PBS. Nude
mice were randomly divided into 3 groups, and with 6
mice in each group. The day mice received cell injection
was counted as day 0. Mice in the control group were
administrated with normal saline by oral gavage once
per day for 10 days from +8 day to +12 day and +15 day
to +19 day while those in DS and DS/Cu groups were
given DS (2.88 mg/20 g per morning) and DS/Cu (DS:
2.88 mg/20 g per morning, Cu: 0.012 mg/20 g per after-
noon) respectively. The dosage used here was determined
by our preliminary experiment. Length and width of the
tumor were measured with a vernier caliper from the
beginning of treatment every other day with the volume
being calculated using the formulaV = a × b2/2 and growth
curve being documented. The weight of each mouse was
also recorded every other day. Mice were sacrificed on day
20, and the tumors were removed for western blotting
analysis.
MTT cytotoxicity assay
Drug cytotoxicity was determined using the colorimetric
MTT assay. Briefly, cells (1 × 105 cells/well) were plated
into 96-well plates containing 100 μl of the growth
medium in the absence or presence of increasing concen-
trations of drugs at 37°C in 5% CO2 for 24 h and 48 h,
MTT (50 μl/well, 5 mg/ml in PBS) was then added and
incubated for 4 h at 37°C. The cells were further treated
with 100 μl DMSO to dissolve the dark blue crystals of
formazan and the absorbance was measured at 570 nm in
a microplate reader (ELX800, BioTEK, USA). All experi-
ments were repeated at least three times with triplicate in
each experiment. The cytotoxicity of DS or DS/Cu was an-
alyzed and concentration-effect curves were generated as
a plot of the fraction of affected cells versus drug concen-
tration. Growth inhibition was expressed as a percentage
of the untreated controls that were processed simultan-
eously. The IC50 was defined as the concentration that
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ance) compared with untreated controls.
Flow cytometric analysis of apoptotic cells
Cells (3 × 105) cultured in 25 cm2 flasks and exposed to
different treatments for 6 h, 12 h, or 24 h were har-
vested respectively, washed twice with ice-cold PBS and
then re-suspended in 500 μl binding buffer. The cells
were further incubated with Annexin V-FITC and Pro-
pidium Iodide for 15 min at room temperature in the
dark according to the manufacturer’s instructions. The
stained cells were analyzed by flow cytometry using
FACS Calibur (BD Biosciences, Oxford, UK) and Cell
Quest (BD Biosciences) software.
Determination of ROS production
ROS production in cells was determined utilizing 2’,7’-
dichlorodi hydro fluorescein diacetate (DCFDA). Briefly,
4 × 105/ml cells were taken in a culture dish and treated
with DS or DS/Cu for 6 h, 12 h or 24 h. After the treat-
ment, cells were collected and DCFDA (Sigma-Aldrich,
Dorset, UK) was added to the cell suspension at a final
concentration of 10 μM. After 30 minutes of incubation
in the dark at 37°C, cells were centrifuged and the pellet
was washed twice with ice-cold PBS. The pellet was then
resuspended in FACS buffer and the fluorescence was
analyzed with FACS Calibur (BD Biosciences, Oxford,
UK) and CellQuest (BD Biosciences) software. DCFDA
fluorescence intensity was measured in FL-1 with an ex-
citation wavelength of 488 nm and an emission wave-
length of 530 nm. The percentage of ROS producing
cells was calculated by counting only those cells, which
produced high levels of ROS.
Western blot analysis
Whole protein (50 μg/lane) from each sample was resolved
in 10% SDS-polyacrylamide gel electrophoresis (PAGE),
transferred to a PVDF membrane (Millipore, UK) and
blotted with various antibodies. Non-specific binding was
avoided by blocking the nitrocellulose membrane with 5%
skimmed milk in TBS-T for 1 h. The 5% skimmed milk in
TBS-T was also used to dilute primary (SAPK/JNK, rabbit
polyclonal, 1:1000, CST; Phospho-SAPK/JNK, rabbit poly-
clonal 1:1000, Cell Signaling techonology; Phospho-c-jun,
rabbit polyclonal, 1:500, Bioworld Technology Co., Ltd., c-
jun, rabbit polyclonal, 1:1000, Santa cruz; P65, rabbit poly-
clonal, 1:1000, Santa Cruz; Nrf2, rabbit polyclonal, 1:1000)
and HRP-conjugated monoclonal secondary (1:5000;
Amersham Pharmacia Biotech, NJ) antibodies. The mem-
branes were incubated with the primary antibodies over-
night at 4°C and in the secondary antibody for 1 h at
room temperature. The quantity of protein loaded was
verified by staining the same membranes with anti-β actin
antibody (1:2000, Sigma-Aldrich, Dorset, UK). The signalswere detected on X-ray films using an ECL Western
blotting detection kit (Amersham, Pharmacia Biotech).
Statistical analysis
All results were analyzed by Student’s t-test and ANOVA
using SPSS 13.0. The statistical significance was indicated
by a p value < 0.05.
Results
The cytotoxicity of DS in both Raji and Molt4 cells was
Cu-dependent
Cytotoxicity of DS or DS/Cu was determined using MTT
assay. In CuCl2 (1 μM)-supplemented medium, DS was
highly cytotoxic to Raji cell lines (IC50_72h: 0.085 ± 0.015 μM;
Figure 1A). DS was also toxic to cancer cell lines in the
complete medium without CuCl2 supplement with higher
IC50 (IC50_72h:0.793 ± 0.08 μM; p <0.001 Figure 1A). To fur-
ther confirm the cytotoxicity of DS or DS/Cu to lymphocyte
derived tumor, we tested another type of tumor cell line
Molt4 in vitro. As shown in Figure 1B, DS/Cu was highly
cytotoxic to Molt4 cells with IC50_24h = 0.435 ± 0.109 μM.
DS alone was also toxic with higher IC50 of 1.314 ±
0.229 μM in Molt4 cells.
Furthermore, apoptosis of Raji cells being treated with
DS at the concentration of IC50_24h (3.3 μM) with or with-
out Cu (1 μM) for 6, 12 and 24 h was analyzed using
Annexin V-FITC/PI staining method (Figure 2A). A higher
apoptotic rate was achieved at any time-point treated by
DS/Cu (P < 0.05; P < 0.01; P < 0.01). It was also observed
that the apoptotic rate of cells treated by DS/Cu was time-
dependent with a higher apoptotic ratio at 24 h than that at
6 h and 12 h (P < 0.001). In addition, Molt4 cells treated
with DS at different concentrations (0.125, 0.25, 0.5, 1,
2 μM) in combination with Cu (1 μM) or without Cu for
24 h were subjected for apoptotic analysis. Except for
0.125 μM DS alone, DS with or without Cu could induce
significant apoptosis in a concentration-dependent manner
with the maximal apoptotic proportion (DS: 70.943 ± 3.987,
DS/Cu: 89.867 ± 4.69%) at a concentration of 2 μM. Inter-
estingly, the apoptosis rate of Molt4 cells that were treated
by DS/Cu was higher (Figure 2B).
DS/Cu significantly increases the ROS level in Raji cells
In accordance with previous studies, our experiment dem-
onstrates that ROS activation is induced by DS/Cu [11]. As
shown in Figure 3, ROS levels were detected after Raji cells
being treated with DS (3.3 μM) or DS/Cu (DS:3.3 μM;
Cu:1.0 μM) at 6 h, 12 h, and 24 h . Both DS and DS/Cu can
increase the ROS activity in a time-dependent manner (DS
vs control :P < 0.01; DS/Cu vs control: P < 0.01). However,
DS/Cu significantly induces ROS activity in Raji cells com-
pared with DS alone, and the highest ROS activity can be
detected in cells treated with DS/Cu at 24 h(DS vs DS/Cu:
6 h: P < 0.01; 12 h: P < 0.001; 24 h: P < 0.001).
Figure 1 The cytotoxicity of DS in Raji and Molt4 cells was Cu-dependent. (A) MTT results of DS and DS/Cu in Raji cells at 72 h (n = 3).
(B) MTT results of DS and DS/Cu in Molt-4 cells at 24 h (n = 3).
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Figure 2 DS with or without Cu induces apoptosis in lymphoid malignant cells. (A) The apoptotic Raji cells was measured by flow
cytometry after treated with disulfiram with or without Cucl2 at different time points ( 6 h,12 h,24 h) (n = 3). (B) Molt-4 cells were treated with
different combination of disulfiram and Cucl2, after which the apoptotic cells were determined by flow cytometry (n = 3).
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Raji cells
Nrf2 is a transcription factor which plays a vital role in
activating antioxidant response that decreases ROS [3]. It
has been reported that the expression of Nrf2 is correlated
with the ROS activity [6]. In line with previous report,
ROS activity increased when Raji cells were treated with
DS or DS/Cu for 12 h (Figure 4A). However, when Raji
cells were exposed to DS or DS/Cu for a longer period of
time (18 h or 24 h for example), the expression of Nrf2
decreased. The decrease of Nrf2 expression level was most
obvious after having been treated with DS or DS/Cu for
24 h (Figure 4A).DS/Cu triggered persistent activation of JNK pathway
Figure 4B shows the effect of DS, Cu or DS/Cu on the ac-
tivation of the JNK pathway. The expression of phosphor-
ylated JNK and c-jun proteins significantly increased in
Raji cells after exposure to DS (3.3 μM) with or without
Cu (1.0 μM), especially in those treated with DS/Cu.
However, the expression of these proteins was only mildly
affected when treated with Cu (1.0 μM) alone.
DS/Cu inhibited NF-κB activity in Raji cell lines
Previous publications have already demonstrated the close
relationship between DS/Cu and NF-κB activity [8]. p65
protein is an important component of NF-κB family and
Figure 3 DS or DS/Cu could induce ROS activity in Raji cells in a time-dependent manner. ROS level of Raji cells after exposure to DS
(3.3 μM) with or without Cu (1 μM) for 6 h, 12 h, and 24 h.
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shows that DS (3.3 μM) with or without Cu (1.0 μM)
inhibits p65 protein expression. The strongest inhibition
was observed in cells treated with DS/Cu.
ROS activation was responsible for DS/Cu-induced JNK,
NF-κB and Nrf2 changes
Previous reports and the data collected from this study
demonstrate that the cytotoxicity of DS is Cu-dependent
[11], indicating ROS might be the mediator of DS/Cu
induced JNK, NF-κB and Nrf2 changes. Figure 5 shows
that when Raji cells were treated with DS (3.3 μM), Cu
(1.0 μM) or DS/Cu in the presence of ROS inhibitor NAC
(10 mM) for 24 h, the activation of JNK pathway, the
inhibition of NF-κB activity and the decrease of Nrf2
expression level by DS/Cu were abolished.
DS/Cu inhibited the growth of xenografts derived from
Raji cells
To determine if DS/Cu had similar activity in vivo, a
lymphoma mouse model was established. Mice in control,
DS, and DS/Cu groups were orally given the same volume
of normal saline, DS, or DS/Cu respectively for 10 days.
All the mice had survived until the end of the experiment.
As shown in Figure 6A and 6B, the mean tumor volume
of mice in DS/Cu group was significantly smaller than DS
and control group, indicating that DS/Cu inhibits the
proliferation of Raji cells in vivo (P < 0.05).
DS/Cu restored the expression of Nrf2 and P65 while
activating JNK pathway in vivo
Our results clearly demonstrate that DS/Cu induces the
apoptosis of Raji cells through inducing ROS activityand activating JNK pathway while inhibiting p65 and
Nrf2 expression in vitro. Next, we examined whether the
mechanism involved might be the same in vivo. As
shown in Figure 7, the expression of Nrf2 and P65 was
reduced when Raji cells were treated with DS or DS/Cu,
and the largest reduction was observed in the DS/Cu
group. Persistent activation of JNK pathway was also
observed in DS or DS/Cu treated groups.
Discussion
Disulfiram is a Food and Drug Administration-approved
anti-alcoholism drug used in clinic for more than 6 decades
with numerous available pre-clinical and clinical data [1].
Previous studies have already demonstrated its low toxicity
to normal tissues [1]. Recently, the anti-cancer ability of
disulfiram has been reported [11]. Moreover, DS can facili-
tate intracellular Cu uptake in cancer cells and potentiate
the cytotoxicity of anticancer drugs in drug resistant and
sensitive breast, colon cancer and leukemia cell lines [12].
We have reported that DS/Cu is cytotoxic and able to
reverse chemoresistance in drug resistant HL60/DOX
leukemia cell line in vitro [10]. However, there was no
report about the cytotoxicity and related molecular
mechanisms of DS/Cu in lymphoid malignant cell lines.
In this study we first demonstrated that DS has a high
cytotoxicity in lymphoid malignant cell lines in a Cu-
dependent manner both in vitro and in vivo. DS/Cu can
significantly induce more apoptosis than DS or Cu
alone in vitro while inhibiting the growth of xenograft
lymphoma in mice. Furthermore, there has been a long
history of using Cu to treat cancer [13]. However, the
intracellular transport of Cu remains to be a major
hurdle for its clinical use. N,N-diethyldithiocarbamte
Figure 5 ROS is the key mediator of DS/Cu induced JNK, NF-κB
and Nrf2 changes. The Raji cell lines were exposed to Cu1.0μM,
DS3.3μM or DS3.3μM/Cu1.0μM in combination with NAC (10 mM) for 24 h.
The expressions of c-jun, p65 and Nrf2 were detected by western blot.
All the proteins detected here were from whole proteins. –VE: control.
Figure 4 The effect of DS/Cu on the expression level of Nrf2 as
well as on JNK and NF-κB pathways. Raji cells were exposed to
DS3.3μM/Cu1 μM , DS 3.3μM or Cu 1μM for indicated time lengths. The
expression levels and phosphorylation status of proteins in JNK (B)
(after 6 hours’ treatment) as well as the expression levels of Nrf2 (A)
(after 24 hours’ treatment) and NF-κB pathways (C) (after 24 hours’
treatment) were detected by western blot. All the proteins detected
here were from whole proteins. –VE: control.
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forming a Cu (deDTC)2 complex which improves the
intracellular trafficking of Cu [5]. Previous publication
has already reported that children bearing lymphoma
have higher serum Cu level than healthy ones. The Cu
concentrations in the serum are associated with the dis-
ease stages [14]. Herein, DS can target cancer cells to
treat lymphoma with little harm to normal tissues.
However, the mechanism of DS/Cu induced apop-
tosis remains unclear. Previous publications demon-
strate that in combination with Cu, DS induces ROS
activity in cancer cell lines [11]. Cancer cells are under
higher ROS stress than normal tissues since theyusually possess high proliferative rate [2]. However,
high levels of ROS can damage DNA, mitochondrial
inner membrane and membrane phospholipids leading
to apoptosis [2]. Thus, generation of ROS might be a
novel method to treat cancers. Recent studies have also
demonstrated that generation of ROS by drugs can
induce apoptosis in lymphoid malignant cell lines [15].
In consistence with these results, our study confirmed
that DS/Cu induces ROS in Raji cell lines which might
contribute to DS/Cu induced apoptosis. When ROS
inhibitor NAC was added, the cytotoxicity of DS/Cu to
Raji cell lines was significantly alleviated.
The c-Jun N-terminal kinase (JNK) signaling pathway
is known to play a critical role in diverse cellular pro-
cesses including regulation of proliferation, differenti-
ation and apoptosis [9]. Moreover, previous studies
indicated that the sustained activation of JNK is essen-
tial for drug-induced apoptosis in lymphoma cell lines
in vitro [16]. Furthermore, ROS are potent activators of
JNK through oxidative inactivation of endogenous JNK
inhibitors, such as JNK phosphatases and glutathione
S-transferase π [4]. In accordance with previous stud-
ies, we found that JNK pathway was persistently (over
24 h) activated (phosphorylation of cJun) by DS/Cu
both in vitro and in vivo and blocked by ROS inhibitor
NAC in vitro, confirming the important role of ROS in
DS/Cu induced apoptosis.
As a double-edged sword, apart from induction of
apoptotic factors, ROS also induces expression of anti-
apoptotic factors. The effect of ROS on cancer cells
depends on the balance between ROS-induced pro- and
anti-apoptotic factors. Lymphoid malignant cell lines
constitutively express high levels of NF-κB, an import-
ant anti-apoptotic factor [16]. However, previous study
has demonstrated that certain NF-κB-regulated genes
play a major role in regulating the amount of ROS
in the cells [16]. ROS have various inhibitory or
Figure 6 Apoptosis of Raji cells could be induced by DS/Cu
in vivo. (A) Tumor volume growth curve. (B) Image of the
subcutaneous lymphoma tumor. *DS/Cu v.s. Control: P < 0.05; #DS/
Cu v.s. DS: P < 0.05.
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sustained ROS generation by DS/Cu in Raji cells, p65,
the vital component of NF-κB, was significantly inhib-
ited by DS/Cu in vitro and in vivo, and this inhibition
can be blocked by NAC.Figure 7 DS/Cu restores the expression of Nrf2 and P65 while
activating JNK pathway in vivo. Representative western blots analysis
of tumor tissue extracts with antibodies against Nrf2, P65 and c-jun.Nrf2 is another important anti-apoptotic factor in-
duced by ROS [3]. Nrf2 is a transcription factor that
plays a vital role in activating antioxidant response
which abolishes ROS activity, detoxifies harmful chemi-
cals and eventually protects cancer cells from chemo-
and radiotherapy-induced damage [3]. It can regulate
various downstream genes with a wide variety of func-
tions, such as cellular redox homeostasis, cell growth
and apoptosis, DNA repair, inflammatory response, and
the ubiquitin-mediated degradation pathway [3]. It has
already been demonstrated that high background nu-
clear levels of Nrf2 in leukemia cells reduce the sensitiv-
ity of cancer cells to proteasome inhibitors [14]. Thus
targeting Nrf2 might be an effective way to induce
cancer cell apoptosis. Our study showed that DS/Cu
induces ROS generation while inhibiting Nrf2 level in
lymphoma Raji cells. Figure 4A showed that Nrf2 level
might increase at low levels of ROS activity but decrease
when ROS activity increases. We also observed the de-
crease of Nrf2 in vivo. Therefore, increase in ROS activ-
ity might cause the level of Nfr2 to decrease and thus
lose its ability to protect lymphoma cells from oxidative
stress and thus induce cell apoptosis. This phenomenon
might due to the destruction effect of ROS on cells.
Since cells from normal tissue usually have lower basal
ROS level and complete protective mechanism, there-
fore the level of ROS will remain relatively low and high
levels of Nrf2 will prevent the cells from ROS induced
damage.
Conclusion
Our study suggests that DS/Cu complex induced apop-
tosis in lymphoid malignant cells both in vitro and in vivo.
Generation of ROS might be the core step in DS/Cu
induced apoptosis. Moreover, ROS-related activation of
JNK pathway as well as inhibition of NF-κB and Nrf2
might also contribute to the induced apoptosis.
Abbreviation
DS: Disulfiram; Cu: Copper; ROS: Reactive Oxygen Species; NAC: N-acetyl-L-
cysteine; MAPK: Mitogen activated protein kinase; JNK: C-Jun NH2-terminal kinase.
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